Default company panoramic image
Logo

InKaryo Corporation

InKaryo develops sequencing based diagnostic products to replace microarray in clinical settings with higher accuracy and lower cost.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Mountain View, CA, USA
  • Currency USD
  • Founded April 2013
  • Employees 4
  • Website inkaryo.com

Company Summary

InKaryo Corporation developed the first sequencing based karyotyping product eKaryotype 3000 that reinvented current analog version of karyotyping into a highly accurate digital diagnostics. Karyotyping has been widely used in postnatal diagnostics of chromosomal aberrations associated with developmental and neurological disorders. eKaryotype shows distinct advantages in the diagnostics at competitive cost comparing to current methods.

Team

  • Default avatar
    Xitong Li
    President

    A PhD from University of Rochester, Xitong co-founded InKaryo in April 2013 and led the development of eKaryotype product. Prior to InKaryo, Xitong was director of bioinformatics and led the sequencing analysis for prenatal verifi™ test at Verinata Health (acquired by Illumina). Prior to that, Xitong built and led bioinformatics team at Genomic Health for cancer diagnostics. He also worked at Ingenuity Systems, PPD Inc, Novartis, and MIT.

  • Default avatar
    Katie Zobeck
    VP, R&D

    A PhD from Cornell University with postdoctoral training from UCSF, Katie is an enthusiast in translating biological sciences to clinical products at InKaryo. She developed next generation sequencing method for RNA expression profiling and genotyping at UCSF. Katie has been a frequent speaker at various research institutions, conferences, scientific forums, and co-authored many high impact publications in molecular genetics.

Advisors

  • Default avatar
    K&L Gates
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    Xitong Li
    Unconfirmed
    Default avatar
    Gianluca Roma
    Unconfirmed
    Default avatar
    Yanjie Dong
    Unconfirmed